Pancreatic Cancer Research

ResearcherMount Sinai HospitalActive in the last 2 years

George Zogopoulos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0482-7086; OpenAlex author ID A5032367500. Sources: ClinicalTrials.gov.

Their work

Papers
50 (first author 0, last author 14)
Trials
1
Grants
0
Labs led
1
Collaborators
207
Papers, trials and grants by year

2012: 1 paper, 1 trial · 2013: none · 2014: none · 2015: 2 papers · 2016: 5 papers · 2017: 2 papers · 2018: 4 papers · 2019: 3 papers · 2020: 7 papers · 2021: 6 papers · 2022: 7 papers · 2023: 3 papers · 2024: 2 papers · 2025: 4 papers · 2026: 4 papers

Papers 50

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Co-author DOI 10.1002/ijc.70592↗
  2. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  3. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  4. Canadian National Pancreas Conference 2025: Recent Advances in Patient-Centred Management of Pancreatic Cancer. Co-author DOI 10.3390/curroncol33100629↗
  5. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  6. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  7. The subclonal footprint of pervasive early dissemination in pancreatic cancer Co-author DOI 10.1101/2025.11.27.690823↗
  8. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Last author DOI 10.1200/po-25-00696↗
  9. Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. Co-author DOI 10.3390/curroncol31100461↗
  10. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  11. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  12. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  13. Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3389/fgene.2023.1282824↗
  14. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Last author DOI 10.1016/j.gie.2021.10.025↗
  15. Preoperative Endoscopic Ultrasound Fine Needle Aspiration Versus Upfront Surgery in Resectable Pancreatic Cancer: A Systematic Review and Meta-analysis of Clin… Co-author DOI 10.1093/jcag/gwab037↗
  16. Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing. Last author DOI 10.1136/jmedgenet-2021-108054↗
  17. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  18. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  19. Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2022.860767↗
  20. Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer? Last author DOI 10.6004/jnccn.2021.7107↗
  21. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  22. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Co-author DOI 10.1016/j.ctrv.2021.102310↗
  23. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  24. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Last author DOI 10.1053/j.gastro.2021.08.036↗
  25. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  26. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. Last author DOI 10.6004/jnccn.2021.7049↗
  27. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.12.010↗
  28. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  29. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  30. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-2803↗
  31. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3724↗
  32. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-1439↗
  33. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Last author DOI 10.3390/genes11091098↗
  34. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  35. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001294↗
  36. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Last author DOI 10.1371/journal.pgen.1008344↗
  37. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  38. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  39. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  40. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research R… Last author DOI 10.1200/po.17.00098↗
  41. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes. Co-author DOI 10.1016/j.ejrad.2017.02.033↗
  42. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Co-author DOI 10.1016/j.ejrad.2017.06.028↗
  43. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Last author DOI 10.1016/j.canlet.2015.10.030↗
  44. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  45. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Co-author DOI 10.1053/j.gastro.2016.08.040↗
  46. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-15-0402↗
  47. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.12834↗
  48. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Last author DOI 10.1016/j.canlet.2015.04.003↗
  49. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Last author DOI 10.3747/co.22.2300↗
  50. Identification of germline genomic copy number variation in familial pancreatic cancer. Co-author DOI 10.1007/s00439-012-1183-1↗

Trials 1

  1. Quebec Pancreas Cancer Study Study director NCT04104230↗

Closest collaborators

The 25 strongest of 207 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 33 shared papers, 2012–2026 · strength 3.03
  2. Jennifer Jane Knox · 18 shared papers, 2018–2026 · strength 1.99
  3. Yifan Wang · 17 shared papers, 2019–2025 · strength 1.98
  4. Grainne Mary O'Kane · 18 shared papers, 2019–2025 · strength 1.97
  5. Robert C. Grant · 19 shared papers, 2016–2025 · strength 1.92
  6. Faiyaz Notta · 16 shared papers, 2016–2026 · strength 1.75
  7. Sandra Elisabeth Fischer · 15 shared papers, 2019–2025 · strength 1.52
  8. Ayelet Borgida · 17 shared papers, 2012–2025 · strength 1.34
  9. Spring Holter · 13 shared papers, 2012–2025 · strength 1.23
  10. Erica S. Tsang · 5 shared papers, 2024–2026 · strength 0.91
  11. Diane M. Simeone · 6 shared papers, 2021–2026 · strength 0.89
  12. Ravi Ramjeesingh · 6 shared papers, 2021–2026 · strength 0.89
  13. Randall E. Brand · 7 shared papers, 2016–2026 · strength 0.88
  14. David F. Schaeffer · 7 shared papers, 2020–2026 · strength 0.87
  15. Daniel John Renouf · 7 shared papers, 2020–2026 · strength 0.87
  16. Barbara T. Grünwald · 7 shared papers, 2020–2025 · strength 0.83
  17. Michelle Chan‐Seng‐Yue · 8 shared papers, 2016–2025 · strength 0.78
  18. Joanna M. Karasinska · 6 shared papers, 2020–2026 · strength 0.77
  19. Zu‐Hua Gao · 6 shared papers, 2016–2022 · strength 0.62
  20. James Thomas Topham · 5 shared papers, 2020–2026 · strength 0.61
  21. Sharlene Gill · 3 shared papers, 2024–2026 · strength 0.61
  22. Mustapha Ali Tehfe · 4 shared papers, 2022–2026 · strength 0.61
  23. Jennifer B. Permuth · 4 shared papers, 2021–2026 · strength 0.57
  24. Jessica N. Everett · 4 shared papers, 2021–2026 · strength 0.56
  25. Bryson W. Katona · 4 shared papers, 2021–2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.